Piramal Pharma Limited is a global pharmaceutical company dealing in contract development, hospital generics, and consumer healthcare products across more than 100 countries.

The company's financial performance has been impacted by a decline in revenue, primarily due to inventory destocking in one major CDMO customer order, highlighting a significant business risk.

Despite financial setbacks, Piramal achieved a notable reduction in net debt by placing a tight control over working capital and capex, emphasizing its financial prudence.

In a challenging market, the company remains steadfast in its commitment to sustainability, reinforcing steps with their 4th Annual Sustainability Report showcasing a reduced net debt and sustainable operations.

Strategically, Piramal is expanding its CDMO capabilities significantly in the US and seeking regulatory approvals to market its complex hospital generics globally, indicating its ambition for growth and market penetration.